Corbus Pharmaceuticals Holdings Inc
Change company Symbol lookup
Select an option...
CRBP Corbus Pharmaceuticals Holdings Inc
IVR-B Invesco Mortgage Capital Inc
EWBC East West Bancorp Inc
RVNC Revance Therapeutics Inc
ZFGN Zafgen Inc
SFOR StrikeForce Technologies Inc
SPLV Invesco S&P 500® Low Volatility ETF
USMV iShares Edge MSCI Min Vol USA ETF
HULYX Hawaiian Tax-Free Trust Class Y
ORNCD Oranco Inc
Go

Health Care : Biotechnology | Small Cap GrowthCompany profile

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Closing Price
$5.30
Day's Change
-0.30 (-5.36%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.64
Day's Low
5.29
Volume
(Below Average)
Volume:
677,475

10-day average volume:
809,106
677,475
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Social data discovery, filtering, and analysis provided by LikeFolio: © SwanPowers, LLC

Copyright © 2019. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.

TD Ameritrade provides access to social media platforms on an "as is" basis, and cannot guarantee that content from social media is always available, that it contains all content from the social media source, or that it contains the most recent or most relevant information from the source.